Open AccessBlood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease
Author(s) -
Scott S. Billecke,
Louis G. D’Alecy,
Raylene Platel,
Steven E. Whitesall,
Kenneth Jamerson,
Robert L. Perlman,
Crystal A. Gadegbeku
Publication year - 2008
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfn500
Subject(s) - asymmetric dimethylarginine , medicine , endocrinology , blood pressure , nitric oxide , renal function , nitric oxide synthase , kidney disease , endogeny , end stage renal disease , arginine , hemodialysis , chemistry , biochemistry , amino acid
Plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is significantly elevated in patients with kidney disease and is a potential risk factor for cardiovascular disease. Here, we tested whether human whole blood (WB), as in rodent blood, can accumulate free ADMA and whether this accumulation is a function of disease burden.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom